Actively Recruiting
Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG
Led by Muğla Sıtkı Koçman University · Updated on 2025-06-18
60
Participants Needed
2
Research Sites
16 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomized, double-blind, prospective clinical trial aims to investigate the effect of remote ischemic preconditioning (RIPC) on myocardial protection in patients with type 2 diabetes mellitus undergoing elective coronary artery bypass graft (CABG) surgery. Perioperative myocardial injury remains a significant concern during CABG, particularly in high-risk patients such as those with diabetes. RIPC is a low-cost, non-invasive intervention that may reduce myocardial damage by enhancing ischemic tolerance through intermittent limb ischemia. Sixty patients aged 40-85 years with type 2 diabetes scheduled for isolated CABG will be randomized to either receive RIPC or standard care. RIPC will be applied through five cycles of upper limb cuff inflation and deflation prior to sternotomy. High-sensitivity troponin T levels will be measured at 24, 48, and 72 hours postoperatively to assess myocardial injury. Secondary outcomes include acute kidney injury (KDIGO classification), maximum vasoactive-inotropic score (VIS) during the first 72 postoperative hours, ICU and hospital length of stay. This study will provide insight into the cardioprotective role of RIPC in diabetic patients undergoing cardiac surgery.
CONDITIONS
Official Title
Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with type 2 diabetes mellitus and receiving medical treatment
- Scheduled for isolated elective coronary artery bypass graft (CABG) surgery
- American Society of Anesthesiologists (ASA) physical status class III or IV
- Age between 40 and 85 years
You will not qualify if you...
- Emergency CABG surgery
- Reoperation (revision surgery)
- Left ventricular ejection fraction (LVEF) less than 40%
- History of cardiac arrest or cardiogenic shock
- Pregnancy
- Clinically significant peripheral arterial disease affecting the upper limbs
- Hepatic dysfunction (bilirubin greater than 20 bcmol/L or INR greater than 2.0)
- Renal failure (eGFR less than 20 mL/min/1.73 m8)
- Ongoing treatment with glibenclamide or nicorandil
- Asthma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Mugla Training and Research Hospital
Muğla, Turkey (Türkiye), 48000
Not Yet Recruiting
2
Mugla Training and Research Hospital
Muğla, Turkey (Türkiye)
Actively Recruiting
Research Team
M
Melike Korkmaz Toker, Associate Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here